Matthew G. Kovac
Associate
Matt Kovac is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. Prior to attending law school, Matt worked in the legal departments of several Bay Area tech companies.
Experience
Matt Kovac is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he practices corporate and securities law. Prior to attending law school, Matt worked in the legal departments of several Bay Area tech companies.
Education
- J.D., University of California College of the Law, San FranciscoCum Laude
- B.A., Princeton University
Admissions
- State Bar of California
Credentials
Education
- J.D., University of California College of the Law, San FranciscoCum Laude
- B.A., Princeton University
Admissions
- State Bar of California
Select Publications
- "Copyright and Choreography: The Negative Costs of the Current Framework for Licensing Choreography and a Proposal for an Alternative Licensing Model," 36 Hastings Communications and Entertainment Law Journal 137, 2013
Insights
Select Publications
- "Copyright and Choreography: The Negative Costs of the Current Framework for Licensing Choreography and a Proposal for an Alternative Licensing Model," 36 Hastings Communications and Entertainment Law Journal 137, 2013
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Adona Medical on $33.5 Million Series C Financing
On July 10, 2024, Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced that it has secured $33.5 million in Series C financing. The financing was led by Cormorant Asset Management and TCP Health Ventures, with participation from Excelestar Ventures, the PA MedTech VC Fund II, Unorthodox Ventures, AMED Ventures, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised Adona Medical on the transaction.
Learn More
Client Highlights
Wilson Sonsini Represents Wildtype in $100 Million Series B
On February 23, 2022, Wildtype, a start-up creating sushi-grade cultivated salmon, announced the completion of a $100 million Series B funding round, the largest for a cultivated seafood company. Wildtype launched in 2016 with a mission to help transform the food system by offering consumers "the most sustainable seafood on earth." Wildtype's salmon is free of mercury, microplastics, antibiotics, and other common contaminants. The round was led by L Catterton, and includes investments from Leonardo DiCaprio, Bezos Expeditions, Temasek, S2G Ventures Oceans and Seafood Fund, Robert Downey Jr.'s FootPrint Coalition, Cargill, and several prominent chefs and professional athletes. Existing investors, including Spark Capital and CRV, participated in the round. Wilson Sonsini Goodrich & Rosati represented Wildtype in the transaction.
Learn More
Recent Events
Speaking Engagements
QB3 & Wilson Sonsini Panel: VC Financings for Early-Stage Life Science Companies
Please join us for a discussion of the basic terms you will encounter in a typical VC financing and a Q&A session with three VCs from the Bay Area life sciences community. What are the best ways to approach fundraising with VCs? What should founders/CEOs avoid when pitching to VCs? What do VCs look for in a life science startup company? What sort of business case/pitch is compelling, from the perspective of a VC? What do all of these investment terms mean?
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.